Third Harmonic Bio Inc (NASDAQ: THRD)’s stock price has decreased by -15.53 compared to its previous closing price of 14.33. However, the company has seen a -16.52% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-10 that SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) — Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in fireside chats at the following upcoming conferences:
Is It Worth Investing in Third Harmonic Bio Inc (NASDAQ: THRD) Right Now?
Additionally, the 36-month beta value for THRD is 2.84. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for THRD is 12.96M and currently, short sellers hold a 21.48% ratio of that float. The average trading volume of THRD on November 05, 2024 was 171.50K shares.
THRD’s Market Performance
THRD’s stock has seen a -16.52% decrease for the week, with a -3.31% drop in the past month and a 9.75% gain in the past quarter. The volatility ratio for the week is 10.30%, and the volatility levels for the past 30 days are at 6.65% for Third Harmonic Bio Inc The simple moving average for the last 20 days is -8.50% for THRD stock, with a simple moving average of 2.83% for the last 200 days.
Analysts’ Opinion of THRD
Many brokerage firms have already submitted their reports for THRD stocks, with Morgan Stanley repeating the rating for THRD by listing it as a “Overweight.” The predicted price for THRD in the upcoming period, according to Morgan Stanley is $20 based on the research report published on August 09, 2024 of the current year 2024.
Stifel, on the other hand, stated in their research note that they expect to see THRD reach a price target of $23. The rating they have provided for THRD stocks is “Buy” according to the report published on June 18th, 2024.
Raymond James gave a rating of “Outperform” to THRD, setting the target price at $18 in the report published on June 07th of the current year.
THRD Trading at -7.07% from the 50-Day Moving Average
After a stumble in the market that brought THRD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.54% of loss for the given period.
Volatility was left at 6.65%, however, over the last 30 days, the volatility rate increased by 10.30%, as shares sank -1.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.09% lower at present.
During the last 5 trading sessions, THRD fell by -16.52%, which changed the moving average for the period of 200-days by +24.67% in comparison to the 20-day moving average, which settled at $13.23. In addition, Third Harmonic Bio Inc saw 10.35% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at THRD starting from BVF PARTNERS L P/IL, who sale 1,000,000 shares at the price of $14.30 back on Oct 29 ’24. After this action, BVF PARTNERS L P/IL now owns 176,692 shares of Third Harmonic Bio Inc, valued at $14,300,000 using the latest closing price.
Conner Edward R., the Chief Medical Officer of Third Harmonic Bio Inc, sale 2,673 shares at $15.00 during a trade that took place back on Oct 28 ’24, which means that Conner Edward R. is holding 0 shares at $40,095 based on the most recent closing price.
Stock Fundamentals for THRD
Current profitability levels for the company are sitting at:
- -29.81 for the present operating margin
- 0.74 for the gross margin
The net margin for Third Harmonic Bio Inc stands at -21.6. The total capital return value is set at -0.1. Equity return is now at value -12.25, with -11.87 for asset returns.
Based on Third Harmonic Bio Inc (THRD), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -6.93. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 8.58.
Currently, EBITDA for the company is -43.92 million with net debt to EBITDA at 10.12. When we switch over and look at the enterprise to sales, we see a ratio of 293.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 41.13.
Conclusion
In conclusion, Third Harmonic Bio Inc (THRD) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
